

NDA 201280/S-021  
NDA 201281/S-025  
NDA 206073/S-022  
NDA 208026/S-013

## **SUPPLEMENT APPROVAL**

Boehringer Ingelheim Pharmaceuticals, Inc.  
Attention: Joerg Schnitzler, Ph.D.  
Senior Associate Director, Regulatory Affairs  
900 Ridgebury Road, P.O. Box 368  
Ridgefield, CT 06877

Dear Dr. Schnitzler:

Please refer to your supplemental new drug applications (sNDAs) dated and received June 17, 2019, and your amendments, submitted under section 505(b) and pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Tradjenta (linagliptin) tablets, Jentadueto (linagliptin and metformin hydrochloride) tablets, Glyxambi (empagliflozin and linagliptin) tablets, and Jentadueto XR (linagliptin and metformin hydrochloride extended-release) tablets.

We also refer to our letter dated May 3, 2019, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for dipeptidyl peptidase-4 (DPP-4) inhibitors, including Tradjenta, Jentadueto, Glyxambi, and Jentadueto XR. This information pertains to the risk of rhabdomyolysis.

These supplemental new drug applications provide for revisions to the labeling for Tradjenta, Jentadueto, Glyxambi, and Jentadueto XR, consistent with our May 3, 2019 letter, and the comments provided in our June 18, 2019, correspondence.

### **APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling with minor editorial revisions listed below and reflected in the enclosed labeling.

- Updated the revision date in the Highlights of the Prescribing Information to “7/19”
- Updated the revision date of the Medication Guide to “July 2019”
- Updated the Copyright information year to “2019” at the end of the Prescribing Information and Medication Guide per prior concurrence with the Applicant

## **WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS**

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.

## **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

NDA 201280/S-021  
NDA 201281/S-025  
NDA 206073/S-022  
NDA 208026/S-013  
Page 3

Because none of these criteria apply to your application, you are exempt from this requirement.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Richard Whitehead, M.S., Regulatory Project Manager, at (301) 796-4945.

Sincerely,

*{See appended electronic signature page}*

William Chong, M.D.  
Deputy Director (Acting)  
Division of Metabolism and Endocrinology Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

#### ENCLOSURES:

- Content of Labeling (Prescribing Information and Medication Guides) for Tradjenta, Jentadueto, Glyxambi, and Jentadueto XR

---

**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**

---

/s/  
-----

WILLIAM H CHONG  
07/01/2019 07:49:20 AM